BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 26702474)

  • 1. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
    J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
    Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor stage mycosis fungoides: a single-center study on clinicopathologic features, treatments, and patient outcome.
    Patrawala SA; Broussard KC; Wang L; Zic JA
    Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.
    Pulitzer M; Myskowski PL; Horwitz SM; Querfeld C; Connolly B; Li J; Murali R
    Pathology; 2014 Dec; 46(7):610-6. PubMed ID: 25393251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
    Raghavan SS; Hong EK; Kim YH; Kim J
    J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformed mycosis fungoides: clinicopathological features and outcome.
    Barberio E; Thomas L; Skowron F; Balme B; Dalle S
    Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
    Diamandidou E; Colome-Grimmer M; Fayad L; Duvic M; Kurzrock R
    Blood; 1998 Aug; 92(4):1150-9. PubMed ID: 9694702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation.
    Bittencourt AL; Oliveira PD; Carvalho-Andrade A; Araújo I
    Int J Dermatol; 2015 Sep; 54(9):e327-31. PubMed ID: 26147565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of CXCR3 and CD30 in mycosis fungoides.
    Nikoo A
    Arch Iran Med; 2012 Mar; 15(3):146-50. PubMed ID: 22369302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
    Nguyen GH; Olson LC; Magro CM
    Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
    Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
    Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
    Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
    Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
    Benner MF; Jansen PM; Vermeer MH; Willemze R
    Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
    Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
    Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.